The curative effects of lamivudine and adefovir dipivoxil combined antiviral treatment on decompensated period hepatitis B liver cirrhosis

Objective:To observe the effects of nucleoside drugs combination therapy against decompensated period Hepatitis B liver cirrhosis. Methods:Sixty-eight cases with decompensated period Hepatitis B liver cirrhosis were divided into three groups randomly:based on the routine therapy,patients in A group were treated with lamivudine 100 mg/d and adefovir dipivoxil 10 mg/d;patients in B group were treated with lamivudine 100 mg/d,and with adefovir dipivoxil 10 mg/d in C group.After treatment for 48 weeks,the ALT recovery rate,HBeAg/anti-HBe sero-conversion rate,HBV DNA negative rate,and Child-pugh score were observed. Results:Through the antiviral treatment in these three groups,no death was happened.The ALT recovery rate in A group had a certain degree improvement with time,and in contrast to B and C group,the ALT recovery rate was increased significantly after 48 weeks treatment.The Child-pugh scores in all group had improved remarkably.HBeAg/anti-HBe sero-conversion rate in A,B,and C group was 20.83%,13.63% and 9.1%,respectively,there had no statistical differences among the three groups(P0.05).HBeAg negative rate in A,B,and C group was 62.5%,27.3% and 22.7%,in contrast to A group,there had significant differences about HBeAg negative rate in B and C group(P0.05). Conclusions:Lamivudine and adefovir dipivoxil combined antiviral treatment for decompensated period Hepatitis B liver cirrhosis can rapidly control the copy of HBV DNA,improve liver function effectively,delay the progress of disease,and finally achieve the treatment goal against liver cirrhosis.